A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer

Upregulation of Notch pathway is associated with poor prognosis in breast cancer. We present the results of a phase I study of an oral selective gamma secretase (GS) inhibitor (critical to Notch signaling), RO4929097 in combination with neoadjuvant chemotherapy for operable triple negative breast ca...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Sardesai, Sagar, Badawi, Mohamed, Mrozek, Ewa, Morgan, Evan, Phelps, Mitch, Stephens, Julie, Wei, Lai, Kassem, Mahmoud, Ling, Yonghua, Lustberg, Maryam, Stover, Daniel, Williams, Nicole, Layman, Rachel, Reinbolt, Raquel, VanDeusen, Jeffrey, Cherian, Mathew, Grever, Michael, Carson, William, Ramaswamy, Bhuvaneswari, Wesolowski, Robert
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7955776/
https://ncbi.nlm.nih.gov/pubmed/31953695
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-00895-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados